<DOC>
	<DOCNO>NCT01620463</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial ass safety tolerability NNC 90-1170 ( liraglutide ) healthy Japanese male subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Liraglutide Healthy Japanese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 27 kg/m^2 , inclusive Clinically relevant abnormality physical examination , laboratory value , vital sign ECG finding screen , judge Investigator SubInvestigator Presence acute chronic illness sufficient invalidate subject 's participation study make unnecessarily hazardous , judged Investigator Blood pressure supine position screening , rest 5 min , outside range 90150 mmHg systolic 4090 mmHg diastolic Heart rate supine position screening , rest 5 min , outside range 40100 beats/min Alcohol intake within 48 hour prior screen Hepatitis B surface antigen , Hepatitis C antibody HIV ( human immunodeficiency virus ) antibodies positive Clinically relevant abnormal history physical finding screening , could interfere objective study safety subject 's participation , judge Investigator History significant allergy hypersensitivity Known suspect allergy trial product related product History drug alcohol abuse Smoking 10 cigarette , equivalent , per day unwilling refrain smoke 3 day prior dose confinement period</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>